Pharma News, 2022

Abbott is already a big player in the wearable glucose-monitoring sector, and has started working on a new device that will measure both glucose and ketones, potentially serving as a warning system...

The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport‘, a designation designed to speed up NHS access to promising new medi...

Veru submitted an Emergency Use Authorization (EUA) application to the FDA for its investigational oral drug candidate sabizabulin for the treatment of moderate-to-severe hospitalized COVID-19 pati...

As Biogen continues to reel from the rollout (or lack thereof) of its FDA-approved Alzheimer’s med Aduhelm, the company is looking elsewhere for promising clinical candidates tackling neurodegen...

Patients with a particular kind of cancer and a particular kind of mutation received a new therapy called dostarlimab and had results not seen in a cancer trial before. ...

Praxis Precision Medicines’ investigational GABA type A receptor drug PRAX-114 failed a phase 2/3 clinical trial that was evaluating the drug’s efficacy and safety as monotherapy for patients w...

New research has found that Pseudomonas bacterium develops resistance much faster than usual to a common ‘last-resort’ antibiotic.

Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have found that oral administration of rapamycin to an Alzheimer’s disease mouse model causes...

For the first time in half a decade, the U.S. Food and Drug Administration’s Cell, Tissue and Gene Therapies Advisory Committee will convene to address two therapies developed by bluebird bio in ...

The UK’s Medicines and Healthcare products Regulatory Agency has approved VBI Vaccines’ PreHevbri three-antigen vaccine for immunization of adults against infection by all known subtypes of th...

A team of researchers from the Brown Cancer Center, the University of Louisville, Peak Neuromonitoring Associates, the University of Texas and the University of Louisville has found that a metabol...

Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower decline in cognitive and functional measures than would be e...